AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Venlafaxine outperformed selective serotonin reuptake inhibitors in achieving remission in major depression, according to a pooled analysis of data from 33 randomized, double-blind, comparative clinical trials.
Venlafaxine is a dual inhibitor of serotonin and norepinephrine reuptake. Many physicians who prescribe it consider it a more effective antidepressant than the selective serotonin reuptake inhibitors (SSRIs). The pooled analysis of 7,611 randomized patients with major depressive disorder supports this impression, Dr. Charles B. Nemeroff said at the annual meeting of the American Psychiatric Association.
This was the largest and most comprehensive pooled analysis ever to examine original data from a complete set of published and unpublished comparative trials involving antidepressants. All 33 randomized trials and the pooled analysis were funded by Wyeth Pharmaceuticals, which markets venlafaxine as Effexor XR.
The 33 trials featured a total of 3,373 patients randomized to venlafaxine, 3,311 to SSRIs, and 927 to placebo. A total of 1,909 patients received immediate-release venlafaxine, while 1,464 received the newer sustained-release formulation of the drug.
The primary end point in the pooled analysis was the rate of remission, defined as a total score of 7 or less on the Hamilton Depression Rating Scale (HAM-D) at week 8. The remission rate was 41% with venlafaxine, ...
Source: HighBeam Research, Depression remission higher with venlafaxine than SSRIs.(Largest...